Skip to main content

Table 1 Demographic data of the 54 statin users in the study cohort. Age, lab values, and survival time is at time of inclusion in the original studies [16, 19]. All values are presented as mean ± SD if not specified otherwise. P values show statistically significant differences between women and men. Survival time is from time of inclusion in the original vitamin D study

From: Differences in discontinuation of statin treatment in women and men with advanced cancer disease

  Total (N = 54) Men (N = 25) Women (N = 29) p
Patients’ characteristics
Age (years) 72 ± 10 71 ± 11 73 ± 8 ns
Age > 75 years, n (%) 20 10 10 ns
Albumin (g/L) 27 ± 7 27 ± 6 27 ± 7 ns
CRP (mg/L) 65 ± 27 63 ± 126 66 ± 82 ns
25-OHD (nmol/L) 45 ± 29 43 ± 26 47 ± 32 ns
ESAS QoL 5.7 ± 2.5 6.5 ± 2.4 5.0 ± 2.4 0.03
History of stroke, n 6 4 2 ns
History of myocardial infarction, n 12 8 4 ns
Survival time (months) 3.3 ± 4.5 2.2 ± 2.5 4.3 ± 5.5 ns
(0.10)
Highest educational level
 University degree 4 2 2 ns
 No university degree 30 14 16 ns
 Unknown 20 9 11 ns
Indication for statin use
 Primary prevention, n 36 13 23  
 Secondary prevention, n 18 12 6 0.03
Type of statin, n
mean dose (mg)
 Simvastatin 41
28 mg
21
31 mg
20
24 mg
ns
 Atorvastatin 10
23 mg
3
27 mg
7
19 mg
ns
 Rosuvastatin 2
10 mg
0 2
10 mg
ns
 Pravastatin 1
20 mg
1
20 mg
0 ns
  1. ESAS QoL: The Edmonton Symptom Assessment System, Quality of life assessment, a scale from 0 to 10
  2. CRP: C reactive protein, 25-OHD: 25-hydroxyvitamin D, ns: non-significant